Sumanta K Pal1, Toni K Choueiri2, Kai Wang3, Depinder Khaira3, Jose A Karam4, Eliezer Van Allen2, Norma A Palma3, Mark N Stein5, Adrienne Johnson3, Rachel Squillace3, Julia A Elvin3, Juliann Chmielecki3, Roman Yelensky3, Evgeny Yakirevich6, Doron Lipson3, Douglas I Lin7, Vincent A Miller3, Philip J Stephens3, Siraj M Ali8, Jeffrey S Ross9. 1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 2. Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. 3. Foundation Medicine, Cambridge, MA, USA. 4. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 6. Department of Pathology and Laboratory Medicine, Warren Alpert School of Medicine at Brown University, Providence, RI, USA. 7. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 8. Foundation Medicine, Cambridge, MA, USA. Electronic address: sali@foundationmedicine.com. 9. Foundation Medicine, Cambridge, MA, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA.
Abstract
BACKGROUND: Collecting duct carcinoma (CDC) is a rare type of renal cell carcinoma (RCC) originating from the renal medulla. Clinical outcomes are poor, and there are no consensus guidelines to guide therapy. OBJECTIVE: To determine genomic alterations (GAs) in a series of patients with locally advanced or metastatic CDC for whom genomic profiling was performed during the course of clinical care. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded blocks or slides were obtained for 17 patients with CDC. DNA was extracted and comprehensive genomic profiling was performed in a laboratory certified under the Clinical Laboratory Improvement Amendments. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Bayesian algorithms and local alignment algorithms were used to detect substitutions and insertions/deletions, respectively. A comparison to normal control samples was used to detect copy number alterations. Clinically relevant GAs (CRGAs) were defined as those linked to approved or investigational targeted therapies. RESULTS AND LIMITATIONS: The median age in the cohort was 53 yr (range 26-73), and 14 primary tumors and three metastatic sites assessed. A total of 36 GAs were detected in this series of patients, with an average of 2.1 GAs per case. The most common GAs were in NF2 (5/17, 29%), SETD2 (4/17, 24%), SMARCB1 (3/17, 18%), and CDKN2A (2/17, 12%). Of nine cases assessed for FH GAs, two patients had FH homozygous loss. A limitation is that targeted interrogation of genes known to be implicated in other cancers was performed, so mutations outside of these cannot be excluded. CONCLUSIONS: Recurrent CRGAs were detected in this series of CDC cases and suggest a possible benefit from targeted therapy. In particular, mTOR inhibitors may be of interest in patients with NF2 alterations. Alterations in FH and SMARCB1 also occurred in a mutually exclusive manner to NF2 alterations. PATIENT SUMMARY: This report provides important genomic insights into collecting duct carcinoma, a rare type of renal cell carcinoma with a very aggressive course. These insights could further rationalize the use of targeted therapies for rare tumors according to the individual genomic alterations harbored.
BACKGROUND: Collecting duct carcinoma (CDC) is a rare type of renal cell carcinoma (RCC) originating from the renal medulla. Clinical outcomes are poor, and there are no consensus guidelines to guide therapy. OBJECTIVE: To determine genomic alterations (GAs) in a series of patients with locally advanced or metastatic CDC for whom genomic profiling was performed during the course of clinical care. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded blocks or slides were obtained for 17 patients with CDC. DNA was extracted and comprehensive genomic profiling was performed in a laboratory certified under the Clinical Laboratory Improvement Amendments. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Bayesian algorithms and local alignment algorithms were used to detect substitutions and insertions/deletions, respectively. A comparison to normal control samples was used to detect copy number alterations. Clinically relevant GAs (CRGAs) were defined as those linked to approved or investigational targeted therapies. RESULTS AND LIMITATIONS: The median age in the cohort was 53 yr (range 26-73), and 14 primary tumors and three metastatic sites assessed. A total of 36 GAs were detected in this series of patients, with an average of 2.1 GAs per case. The most common GAs were in NF2 (5/17, 29%), SETD2 (4/17, 24%), SMARCB1 (3/17, 18%), and CDKN2A (2/17, 12%). Of nine cases assessed for FH GAs, two patients had FH homozygous loss. A limitation is that targeted interrogation of genes known to be implicated in other cancers was performed, so mutations outside of these cannot be excluded. CONCLUSIONS: Recurrent CRGAs were detected in this series of CDC cases and suggest a possible benefit from targeted therapy. In particular, mTOR inhibitors may be of interest in patients with NF2 alterations. Alterations in FH and SMARCB1 also occurred in a mutually exclusive manner to NF2 alterations. PATIENT SUMMARY: This report provides important genomic insights into collecting duct carcinoma, a rare type of renal cell carcinoma with a very aggressive course. These insights could further rationalize the use of targeted therapies for rare tumors according to the individual genomic alterations harbored.
Authors: Primo N Lara; Andreas M Heilmann; Julia A Elvin; Mamta Parikh; Ralph de Vere White; Regina Gandour-Edwards; Christopher P Evans; Chong-Xian Pan; Alexa B Schrock; Rachel Erlich; Jeffrey S Ross; Philip J Stephens; John McPherson; Vincent A Miller; Siraj M Ali Journal: JCO Precis Oncol Date: 2017-11-02
Authors: Sabina Signoretti; Catherine J Wu; Sachet A Shukla; Toni K Choueiri; David A Braun; Yue Hou; Ziad Bakouny; Miriam Ficial; Miriam Sant' Angelo; Juliet Forman; Petra Ross-Macdonald; Ashton C Berger; Opeyemi A Jegede; Liudmilla Elagina; John Steinharter; Maxine Sun; Megan Wind-Rotolo; Jean-Christophe Pignon; Andrew D Cherniack; Lee Lichtenstein; Donna Neuberg; Paul Catalano; Gordon J Freeman; Arlene H Sharpe; David F McDermott; Eliezer M Van Allen Journal: Nat Med Date: 2020-05-29 Impact factor: 53.440
Authors: Maria I Carlo; Joshua Chaim; Sujata Patil; Yelena Kemel; Alison M Schram; Kaitlin Woo; Devyn Coskey; Gouri J Nanjangud; Martin H Voss; Darren R Feldman; James J Hsieh; A Ari Hakimi; Ying-Bei Chen; Robert J Motzer; Chung-Han Lee Journal: Clin Genitourin Cancer Date: 2017-04-26 Impact factor: 2.872
Authors: Amishi Y Shah; Jose A Karam; Gabriel G Malouf; Priya Rao; Zita D Lim; Eric Jonasch; Lianchun Xiao; Jianjun Gao; Ulka N Vaishampayan; Daniel Y Heng; Elizabeth R Plimack; Elizabeth A Guancial; Chunkit Fung; Stefanie R Lowas; Pheroze Tamboli; Kanishka Sircar; Surena F Matin; W Kimryn Rathmell; Christopher G Wood; Nizar M Tannir Journal: BJU Int Date: 2016-12-09 Impact factor: 5.588
Authors: Shannon M White; Maria Laura Avantaggiati; Ivan Nemazanyy; Cristina Di Poto; Yang Yang; Mario Pende; Geoffrey T Gibney; Habtom W Ressom; Jeffery Field; Michael B Atkins; Chunling Yi Journal: Dev Cell Date: 2019-05-06 Impact factor: 12.270
Authors: Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou Journal: Mod Pathol Date: 2021-03-04 Impact factor: 8.209
Authors: Gabriel G Malouf; Eva Compérat; Hui Yao; Roger Mouawad; Veronique Lindner; Nathalie Rioux-Leclercq; Virginie Verkarre; Xavier Leroy; Linda Dainese; Marion Classe; Jean-Luc Descotes; Philippe Barthelemy; Mokrane Yacoub; Morgan Rouprêt; Jean-Christophe Bernhard; Chad J Creighton; Jean-Philippe Spano; Xiaoping Su; David Khayat Journal: Sci Rep Date: 2016-08-03 Impact factor: 4.379
Authors: Pedram Argani; Victor E Reuter; John N Eble; Ljiljana Vlatkovic; Oksana Yaskiv; David Swanson; Brendan C Dickson; Cristina R Antonescu; Andres Matoso; Jeffrey Gagan; Doreen N Palsgrove Journal: Am J Surg Pathol Date: 2020-07 Impact factor: 6.298